Fusion Antibodies PLC Notice of AGM (2755K)
September 01 2021 - 2:00AM
UK Regulatory
TIDMFAB
RNS Number : 2755K
Fusion Antibodies PLC
01 September 2021
Fusion Antibodies plc
("Fusion" or the "Company")
Notice of AGM
Fusion Antibodies plc (AIM: FAB), specialists in pre-clinical
antibody discovery, engineering and supply for both therapeutic
drug and diagnostic applications, announces that it is today
posting to shareholders a copy of the Company's annual report and
accounts for the year ended 31 March 2021 ("Accounts") and notice
of the Company's annual general meeting ("AGM"), to be held at
11.00 a.m. on 24 September 2021 at The Malone Hotel, 60 Eglantine
Avenue, Malone Road, Belfast BT9 6DY. A copy of the Accounts and
AGM notice will shortly be available from the Company's website,
www.fusionantibodies.com .
The Company is pleased to be able to hold an open AGM this year,
however, the Directors are still taking a cautious view as the
Company cannot predict whether local travel or meeting restrictions
may be introduced at the time of the meeting. Therefore, to
minimise any risks, shareholders are encouraged to appoint the
meeting Chair as proxy.
Enquiries:
Fusion Antibodies plc www.fusionantibodies.com
Richard Jones, Chief Executive Officer Via Walbrook PR
James Fair, Chief Financial Officer
Allenby Capital Limited Tel: +44 (0)20 3328
5656
James Reeve (Corporate Finance)
Tony Quirke (Sales and Corporate Broking)
Walbrook PR Tel: +44 (0)20 7933 8780 or fusion@walbrookpr.com
Anna Dunphy Mob: +44 (0)7876 741
001
Paul McManus Mob: +44 (0)7980 541
893
About Fusion Antibodies plc
Fusion is a Belfast based contract research organisation ("CRO")
providing a range of antibody engineering services for the
development of antibodies for both therapeutic drug and diagnostic
applications.
The Company's ordinary shares were admitted to trading on AIM on
18 December 2017. Fusion provides a broad range of services in
antibody generation, development, production, characterisation and
optimisation. These services include antigen expression, antibody
production, purification and sequencing, antibody humanisation
using Fusion's proprietary CDRx (TM) platform and the production of
antibody generating stable cell lines to provide material for use
in clinical trials. Since 2012, the Company has successfully
sequenced and expressed over 250 antibodies and successfully
completed over 200 humanisation projects and has an international,
blue-chip client base, which has included eight of the top 10
global pharmaceutical companies by revenue.
The Company was established in 2001 as a spin out from Queen's
University Belfast. The Company's mission is to enable
pharmaceutical and diagnostic companies to develop innovative
products in a timely and cost-effective manner for the benefit of
the global healthcare industry. Fusion Antibodies provides a broad
range of services in antibody generation, development, production,
characterisation and optimisation.
Fusion Antibodies growth strategy is based on combining the
latest technological advances with cutting edge science to deliver
new platforms that will enable Pharma and Biotech companies get to
the clinic faster, with the optimal drug candidate and ultimately
speed up the drug development process.
The global monoclonal antibody therapeutics market was valued at
$135.4 billion in 2018 and is forecast to surpass $212.6 billion in
2022, an increase at a CAGR of 12.0 per cent. for the period 2018
to 2022. In 2017, seven of the world's ten top selling drugs were
antibody-based therapeutics with the combined annual sales of these
drugs exceeding $63.2 billion.
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
RNS may use your IP address to confirm compliance with the terms
and conditions, to analyse how you engage with the information
contained in this communication, and to share such analysis on an
anonymised basis with others as part of our commercial services.
For further information about how RNS and the London Stock Exchange
use the personal data you provide us, please see our Privacy
Policy.
END
NOAPBMATMTTJBJB
(END) Dow Jones Newswires
September 01, 2021 02:00 ET (06:00 GMT)
Fusion Antibodies (LSE:FAB)
Historical Stock Chart
From Mar 2024 to Apr 2024
Fusion Antibodies (LSE:FAB)
Historical Stock Chart
From Apr 2023 to Apr 2024